Kapitel 76: Maligne Lymphome


Arcaini L, Paulli M, Boveri E et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer 2004;100(1):107-15


Betticher DC, Gmartinelli G, Radford JA et al. (2006) Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL) Annals Oncol 17: 1546-1552
Chen CJ, Skingley P, Meyer RM (2000) A comparison of outcomes of elderly patients with aggressive histology lymphoma (AHL) who were entered or not entered on to a randomized phase II trial. Leukemia Lymphoma 38: 327–334


Fanin R, Silvestri F, Geromin A et al. (1996) Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: sequential intensive treatment with the F-MACHOP regimen (+/-- radiotherapy) and autologous bone marrow transplantation. Blood 87: 1243–1248


Gallamini A, Zaja F, Gargantini L et al. (2005) CHOP chemotherapy plus Campath-1H (CHOP-C) as first line treatment in patients with peripheral T-cell lymphoma (PTCL) Blood 106:935a


Hoelzer D, Baur KH, Giagounidis A et al. (2003) Short intensive chemotherapy with rituximab seems successful in Burkitt NHL, mature B-ALL and other high-grade B-NHL. Blood 102:236


Hu S, Du MQ, Park SM et al. (2006) cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. J Clin Invest;116(1):174-81


IARC (2001) Tumours of haemotopoietic and lymphoid tissue. 1 ed. IARC Press, Lyon

IARC (2008) Tumours of haemotopoietic and lymphoid tissue. 2 ed. IARC Press, Lyon


Liu H, Ye H, Ruskone-Fourmestraux A et al. (2002) T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology;122(5):1286-94


Raffeld M, Jaffe ES (1991) bcl-1, t (11;14), and mantle cell-derived lymphomas. Blood 78: 259–263
Raffeld M, Jaffe ES (1991) bcl-1, t (11;14), and mantle cell-derived lymphomas. Blood 78: 259–263


Stein RS, Greer JP, Goodman S et al. (1999). High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin. Bone Marrow Transplant 23: (3):227–233


Sweetenham JW, Pearce R, Philip T et al. (1994) High-dose chemotherapy and autologous bone marrow transplantation for intermediate and high grade non-Hodgkin’s lymphoma in patients aged 55 years and over: results from the EMBT. Bone Marrow Transplant 14: 981–987

Swerdlow SH, Campo E, Harris NL et al. (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. WHO Press, Genf, Schweiz


Tilly H, Mounier N, Coiffier B et al. (2001) Superiority of the ACVBP regimen over standard CHOP in the treatment of advanced aggressive NHL: A Study from the GELA. Hematology J 2: 1


Tirelli U, Errante D, Van Glabbeke M et al. (1998) CHOP is the standard regimen in patients >or = 70 years of age with intermediate-grade and high-grade non-Hodgkin’s lymphoma: results of a randomized study of the European


van Krieken JH, Hoeve MA. Epidemiological and prognostic aspects of gastric MALT-lymphoma. Recent Results Cancer Res 2000; 156: 3–8


Vose J, Link BK, Grossbard ML et al. (1999) Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated immediate- or high grade NHL Blood 94: 89a


Werner CA, Dohner H, Joos S et al. (1997) High-level DNA amplifications are common genetic aberrations in B-cell neoplasms. Am J Pathol 151: 335–342


